“Kallay’s speech presages greater attention by U.S. antitrust authorities on anticompetitive conduct arising out of collective action by market dominant players within an SDO.” “Royalty-free” is an ...
DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering. Royalty Rates in Pharmaceutical and Biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results